Publications:

Predictive mutation signature of immunotherapy benefits in NSCLC based on machine learning algorithms.

Frontiers In Immunology

Liu, Zhichao Z; Lin, Guo G; Yan, Zeping Z; Li, Linduo L; Wu, Xingchen X; Shi, Jingrong J; He, Jianxing J; Zhao, Lei L; Liang, Hengrui H; Wang, Wei W

Publication Date: 2022

Variant appearance in text: JAK2: 2796A>T; L932F

PubMed Link: 36238300

Variant Present in the following documents:

• Table_1.xlsx, sheet 4

View BVdb publication page

EPHA5 mutation was associated with adverse outcome of atezolizumab treatment in late-stage non-small cell lung cancers.

Bmc Pulmonary Medicine

Li, Zhenxiang Z; Zhou, Qing Q; Wang, Qi Q; Wang, Haiyong H; Yue, Weiming W

Publication Date: 2022-09-19

Variant appearance in text: JAK2: 2796A>T; L932F

PubMed Link: 36123678

Variant Present in the following documents:

• 12890_2022_2161_MOESM2_ESM.xlsx, sheet 1

View BVdb publication page

Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance.

Scientific Reports

Kesarwani, Meenu M; Huber, Erika E; Kincaid, Zachary Z; Evelyn, Chris R CR; Biesiada, Jacek J; Rance, Mark M; Thapa, Mahendra B MB; Shah, Neil P NP; Meller, Jarek J; Zheng, Yi Y; Azam, Mohammad M

Publication Date: 2015-09-30

Variant appearance in text: JAK2: L932F

PubMed Link: 26419724

Variant Present in the following documents:

• Main text
• srep14538.pdf

View BVdb publication page